关于M2BPGi治疗慢性肝病的临床有用性的专家共识
Tai-Chung Tseng1, Yao-Chun Hsu2, Tung-Hung Su3
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan; Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.
Journal of the Formosan Medical Association = Taiwan yi zhi
|August 24, 2025
概括
作为评估肝纤维化和预测慢性肝病中的肝细胞癌 (HCC) 的非侵入性生物标志物,Mac-2结合蛋白糖化异构体 (M2BPGi) 是有前途的. 它在临床管理中表现优于一些常规标志物和辅助物,但需要进一步验证.
科学领域:
- 肝病学
- 生物标志物发现
- 临床诊断
背景情况:
- 慢性肝病对全球健康构成负担,通常会发展为纤维化,肝硬化和肝细胞癌 (HCC).
- 精确的肝纤维化分期对于患者的治疗至关重要,但肝脏活检是侵入性的.
- 现有的非侵入性生物标志物如APRI和FIB-4在评估纤维化和预测HCC风险方面存在局限性.
研究的目的:
- 评估Mac-2结合蛋白糖化异构体 (M2BPGi) 作为肝纤维化和HCC风险分层的新型非侵入性生物标志物的有用性.
- 将M2BPGi与慢性肝病中的常规生物标志物的性能进行比较.
主要方法:
- 对慢性肝病中的M2BPGi现有文献进行系统审查和分析.
- 评估M2BPGi与纤维化严重程度的相关性及其对HCC发展的预测价值.
- 在不同患者群体中比较M2BPGi与APRI和FIB-4的性能.
主要成果:
- 在慢性乙型肝炎 (CHB) 中,M2BPGi水平与纤维化严重程度相关,其表现优于APRI,并且表现与FIB-4相似,特别是在ALT爆发期间.
- 在接受治疗和未接受治疗的CHB患者中,M2BPGi显示出HCC的预测价值,并确定了风险分层的截止值.
- 在慢性型肝炎中,M2BPGi有助于纤维化阶段和预测HCC治疗后;在MASLD中,它与晚期纤维化相关,但需要进一步验证.
结论:
- M2BPGi是评估肝纤维化和预测各种慢性肝病中HCC风险的有希望的非侵入性生物标志物.
- 需要进行进一步的研究以标准化M2BPGi的临界值,并验证其在不同人群中的有效性,特别是用于MASLD的长期HCC风险预测.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
128
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
128
01:30Acute Pancreatitis II: Clinical Manifestations and Management
176
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
176
01:23Gastritis III: Clinical Manifestations and Management
474
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
474
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419
01:26Diseases of the Liver and Gallbladder
976
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
976
01:29Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189